MSLE Satellos Bioscience Inc.

$9.61

Satellos Bioscience Inc. (MSLE) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $0.35 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -1.7% since its last earnings release on August 13, 2026.

Satellos Bioscience Missed Consensus Estimates
Thursday, August 13, 2026 · 5:02 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 12
Thursday · After Close
Earnings Whisper
-
vs ($0.35)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $9.61

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Satellos Bioscience Inc.

Satellos Bioscience Inc. is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company's lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc., formerly known as iCo Therapeutics Inc., is based in Toronto, Ontario.

Sector

Healthcare

Industry

Biotechnology